For Moderna, the long-promised leap from Covid vaccine maker to cancer-treatment contender suddenly looks less theoretical. For melanoma patients, though, the breakthrough remains a powerful early signal rather than a finished treatment.

On Wednesday, Moderna and Merck said their personalized mRNA vaccine, intismeran autogene, met both main goals in a Phase 3 trial among patients with high-risk melanoma whose tumors had been surgically removed. The combination of the vaccine and Merck’s Keytruda kept patients free of recurrence or spread longer than Keytruda alone—the first late-stage success reported for a therapy of this kind.¹

The vaccine is tailored from each patient’s tumor sample, training the immune system to identify the particular mutations in that cancer. The 1,137-patient trial focused on an especially dangerous setting: melanoma that had grown deeply, reached nearby lymph nodes or, in some cases, spread further.

Earlier results from the same combination had suggested a 49% reduction in the risk of recurrence or death and a 59% reduction in distant metastasis or death versus Keytruda alone. But the companies have not yet released the new Phase 3 figures, saying only that they were “statistically significant and clinically meaningful.”¹ Full results are due at a medical conference before the companies approach regulators.

The market moved faster than the scientific process. Moderna shares more than doubled in early trading, while Merck also rose, reflecting investor confidence that mRNA technology could finally become a broader oncology platform.

Researchers and company leaders framed the news as a potential shift in post-surgery care. Trial investigator Georgina Long called it “a landmark moment for adjuvant melanoma treatment,” saying the pairing could help patients remain cancer-free longer.¹ Moderna CEO Stéphane Bancel, meanwhile, said an individualized mRNA cancer treatment had moved from aspiration toward reality.¹

The optimism is substantial, but the outstanding data matter. Regulators, doctors and patients will need to see the size of the benefit, durability and safety profile before a stock-market surge can become a new standard of care.